AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 May 2014 11:00 AM
RNS
Total Voting Rights
30 Apr 2014 03:29 PM
BZW
Form 8.3 - AstraZeneca Plc
30 Apr 2014 02:24 PM
BZW
Form 8.3 - Astrazeneca Plc
30 Apr 2014 02:09 PM
BZW
Form 8.3 - AstraZeneca PLC
30 Apr 2014 11:00 AM
RNS
Rule 2.10 Announcement
29 Apr 2014 04:30 PM
RNS
Rule 2.10 Announcement
29 Apr 2014 03:32 PM
BZW
Form 8.3 - AstraZeneca Plc
29 Apr 2014 02:46 PM
BZW
Form 8.3 - AstraZeneca PLC
29 Apr 2014 01:38 PM
BZW
Form 8.3 - Astrazeneca Plc
29 Apr 2014 10:52 AM
BZW
Form 8.3 - AstraZeneca PLC
29 Apr 2014 08:36 AM
BZW
Form 8.3 - AstraZeneca PLC
28 Apr 2014 11:34 AM
BZW
Form 8.3 - Astrazeneca Plc - Replacement
28 Apr 2014 10:41 AM
BZW
Form 8.3 - Astrazeneca Plc
28 Apr 2014 10:35 AM
RNS
Statement Regarding Pfizer Announcement
24 Apr 2014 05:20 PM
RNS
Result of AGM
24 Apr 2014 07:08 AM
RNS
1st Quarter Results - Part 2
24 Apr 2014 07:08 AM
RNS
1st Quarter Results
23 Apr 2014 09:00 AM
RNS
Notice of Results
01 Apr 2014 02:00 PM
RNS
Director/PDMR Shareholding
01 Apr 2014 11:00 AM
RNS
Total Voting Rights
31 Mar 2014 02:00 PM
RNS
Director/PDMR Shareholding
31 Mar 2014 02:00 PM
RNS
Director/PDMR Shareholding
31 Mar 2014 02:00 PM
RNS
Director/PDMR Shareholding
26 Mar 2014 11:00 AM
RNS
Director/PDMR Shareholding
21 Mar 2014 07:00 AM
RNS
Filing of Annual Report on Form 20-F with SEC
20 Mar 2014 11:00 AM
RNS
Annual Financial Report
20 Mar 2014 11:00 AM
RNS
Directorate Change
19 Mar 2014 03:00 PM
RNS
Director/PDMR Shareholding
12 Mar 2014 07:00 AM
RNS
AstraZeneca announces sale of Alderley Park site
03 Mar 2014 04:00 PM
RNS
Total Voting Rights
03 Mar 2014 07:00 AM
RNS
US FDA APPROVES BYDUREON? PEN
25 Feb 2014 06:24 PM
RNS
FDA Approves Orphan Drug Myalept
12 Feb 2014 03:30 PM
RNS
Director/PDMR Shareholding
11 Feb 2014 05:00 PM
RNS
Director/PDMR Shareholding
10 Feb 2014 05:30 PM
RNS
Director/PDMR Shareholding
07 Feb 2014 03:30 PM
RNS
Director/PDMR Shareholding
06 Feb 2014 07:00 AM
RNS
Pipeline Table
06 Feb 2014 07:00 AM
RNS
Final Results
05 Feb 2014 09:00 AM
RNS
Notice of Results
03 Feb 2014 04:30 PM
RNS
Total Voting Rights
03 Feb 2014 07:00 AM
RNS
AZ completes BMS diabetes acquisition
27 Jan 2014 10:30 AM
RNS
Holding(s) in Company
22 Jan 2014 07:00 AM
RNS
Xigduo approved in EU for type 2 diabetes
17 Jan 2014 10:42 AM
RNS
Replacement re block listing application
17 Jan 2014 07:00 AM
RNS
Block Listing Application
14 Jan 2014 07:00 AM
RNS
AstraZeneca provides strategy update at JP Morgan
13 Jan 2014 07:00 AM
RNS
US FDA APPROVES FARXIGAT (DAPAGLIFLOZIN)
09 Jan 2014 07:00 AM
RNS
US FDA Approval of Farxiga (dapagliflozin)
02 Jan 2014 04:00 PM
RNS
Total Voting Rights
27 Dec 2013 07:13 AM
RNS
AZ and Shionogi extend Crestor agreement

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings